Novaliq employs an innovative carrier system for topical drug delivery in particular for poorly soluble drugs. This liquid carrier system is based on a unique class of partially fluorinated substances, semifluorinated alkanes. They have unique properties covered by a strong patent portfolio that can be used for a variety of administration routes and purposes. Routes of administration include among others ocular, dermal, buccal and nasal. The unique properties include solubilization of poorly soluble drugs, serving as an oxygen carrier and modulating pharmacokinetic behavior of the whole system.
Novaliq's strategy is to valorize its assets by
(a) developing poorly met medical need products using the unique features of their SFA platform
(b) out-licensing their developed clinical stage and market-ready products to suitable distribution partners, and
(c) offering their delivery platform for improved delivery of drug compounds brought by their partners for co-development.